<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01309932</url>
  </required_header>
  <id_info>
    <org_study_id>AI452-008</org_study_id>
    <secondary_id>2010-022568-11</secondary_id>
    <nct_id>NCT01309932</nct_id>
  </id_info>
  <brief_title>Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin</brief_title>
  <acronym>D-LITE</acronym>
  <official_title>A Phase 2B, Randomized Study to Evaluate the Safety and Efficacy of Pegylated Interferon Lambda (BMS-914143) Administered With Ribavirin Plus a Single Direct Antiviral Agent (BMS-790052 or BMS-650032) Versus Pegasys Administered With Ribavirin (Part A) and of Pegylated Interferon Lambda (BMS-914143) Administered With or Without Ribavirin Plus 2 Direct Antiviral Agents (BMS-790052 and BMS-650032) (Part B) in Chronic Hepatitis C Genotype-1 Treatment naïve Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if combination therapy with Pegylated Interferon
      Lambda (BMS-914143) plus Ribavirin (RBV) with a single direct antiviral agent (BMS-790052 or
      BMS-650032) for 24 weeks is effective and safe for treatment of Chronic Hepatitis C (CHC)
      compared to current standard therapy with Pegylated Interferon Alpha-2a plus RBV for 48
      weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Classification: Pharmacokinetics/ Pharmacodynamics
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability (as measured by the frequency of serious adverse events (SAEs), dose reductions and discontinuations due to adverse events (AEs)</measure>
    <time_frame>Up to end of treatment ( maximum of 48 weeks) plus 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Antiviral activity as determined by the proportion of Hepatitis C virus (HCV) genotype 1 subjects with 24-week sustained virologic response (SVR24)</measure>
    <time_frame>At end of treatment (maximum of 48 weeks)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Antiviral activity as determined by the proportion of Hepatitis C virus (HCV) genotype 1 subjects with 24-week sustained virologic response (SVR24)</measure>
    <time_frame>Post-treatment Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of HCV genotype 1 subjects with Protocol definition of virologic response (PDR) for Part A and Part B</measure>
    <time_frame>Weeks 4, Weeks 12 and post-treatment Weeks 24</time_frame>
    <description>Part A PDR is defined as HCV RNA at Week 4 &lt; LLOQ and Week 12 undetectable
Part B PDR is defined as HCV RNA at Week 2 ≥ 2 log10 decrease (or &lt; Lower limit of quantitation (LLOQ) if baseline HCV RNA &lt; 2400 IU/mL), Week 4 &lt; LLOQ and Week 12 undetectable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with either a 2-log or greater decrease in Hepatitis C virus (HCV) Ribonucleic acid (RNA) levels from baseline or undetectable levels of HCV RNA</measure>
    <time_frame>Weeks 2, Weeks 4 and Weeks 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with viral breakthrough, defined as confirmed &gt; 1 log10 increase in HCV RNA over nadir or confirmed HCV RNA ≥ Lower limit of quantitation (LLOQ) after confirmed undetectable HCV RNA while on treatment</measure>
    <time_frame>Post-treatment Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with undetectable HCV RNA at the end of treatment that develop detectable levels of HCV RNA in the post-treatment follow-up period</measure>
    <time_frame>Post-treatment Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum HCV Ribonucleic acid (RNA) levels over time</measure>
    <time_frame>Days 1, 3, Weeks 1, 2, 4, 6, 8, 12, 16, 20, and end of treatment (Week 16, 24 or 48 depending on treatment assignment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with undetectable HCV RNA over time</measure>
    <time_frame>Days 1, 3, Weeks 1, 2, 4, 6, 8, 12, 16, 20, and end of treatment (Week 16, 24 or 48 depending on treatment assignment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to viral clearance, defined as an absence of detectable HCV RNA</measure>
    <time_frame>Day 1, 3, Week 1, 2, 4, 6, 8, 12, 24, 36, end of treatment (Week 48), Post-Treatment at Week 4, 12, 24, 36, 48, and 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of pegIFNλ and pegIFNα-2a and plasma levels of BMS-790052 and BMS-650032: In PK sub-study group Maximum observed serum/plasma concentration (Cmax)</measure>
    <time_frame>Cmax will be determined at Dose 5 (Study Visit Week 4: 0 - 12 h for BMS-650032, 0 - 24 h for BMS-790052, and 0 - 168 h for pegIFNλ and pegIFNα-2a)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of pegIFNλ and pegIFNα-2a and plasma levels of BMS-790052 and BMS-650032: In PK sub-study group Time to maximum concentration (Tmax)</measure>
    <time_frame>Tmax will be determined at Dose 5 (Study Visit Week 4: 0 - 12 h for BMS-650032, 0 - 24 h for BMS-790052, and 0 - 168 h for pegIFNλ and pegIFNα-2a)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of pegIFNλ and pegIFNα-2a and plasma levels of BMS-790052 and BMS-650032: In PK sub-study group Minimal observed serum/plasma concentration (Cmin)</measure>
    <time_frame>Cmin will be determined at Dose 5 (Study Visit Week 4: 0 - 12 h for BMS-650032, 0 - 24 h for BMS-790052, and 0 - 168 h for pegIFNλ and pegIFNα-2a)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of pegIFNλ and pegIFNα-2a and plasma levels of BMS-790052 and BMS-650032: In PK sub-study group Area under the serum/plasma concentration-time curve during one dose interval AUC(TAU)</measure>
    <time_frame>AUC(TAU) will be determined at Dose 5 (Study Visit Week 4: 0 - 12 h for BMS-650032, 0 - 24 h for BMS-790052, and 0 - 168 h for pegIFNλ and pegIFNα-2a)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of pegIFNλ and pegIFNα-2a and plasma levels of BMS-790052 and BMS-650032: In all subjects, trough concentrations will be assessed (Ctrough)</measure>
    <time_frame>Troughs at baseline (week 0), weeks 2, 4, 8, 12, 16, and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with 12-week sustained virologic response (SVR12), defined as undetectable HCV RNA</measure>
    <time_frame>At end of treatment (maximum of 48 weeks) and follow-up Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with 4-week sustained virologic response (SVR4), defined as undetectable HCV RNA</measure>
    <time_frame>At end of treatment (maximum of 48 weeks) and follow-up Week 4</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">165</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>A1: pegIFNλ+BMS-790052+Placebo for BMS-650032+Ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A2: pegIFNλ+BMS-650032+Placebo for BMS-790052+Ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A3: pegIFNα-2a+PBO for BMS-790052+PBO for BMS-650032+RBV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Part A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A4: pegIFNλ+BMS-790052+BMS-650032+Ribavirin (24 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A5: pegIFNλ+BMS-790052+BMS-650032+Ribavirin (16 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A6: pegIFNλ+BMS-790052+BMS-650032+Placebo for RBV (24 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A7: pegIFNλ+BMS-790052+BMS-650032+Placebo for RBV (16 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pegylated Interferon Lambda (pegIFNλ)</intervention_name>
    <description>Solution, Subcutaneous, 180 μg/mL, Once weekly, 24 or 48 weeks depending on response</description>
    <arm_group_label>A1: pegIFNλ+BMS-790052+Placebo for BMS-650032+Ribavirin</arm_group_label>
    <arm_group_label>A2: pegIFNλ+BMS-650032+Placebo for BMS-790052+Ribavirin</arm_group_label>
    <other_name>BMS-914143</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-790052 (NS5A Inhibitor)</intervention_name>
    <description>Tablets, Oral, 60 mg, Once daily, 24 weeks</description>
    <arm_group_label>A1: pegIFNλ+BMS-790052+Placebo for BMS-650032+Ribavirin</arm_group_label>
    <arm_group_label>A4: pegIFNλ+BMS-790052+BMS-650032+Ribavirin (24 weeks)</arm_group_label>
    <arm_group_label>A6: pegIFNλ+BMS-790052+BMS-650032+Placebo for RBV (24 weeks)</arm_group_label>
    <other_name>BMS-790052</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin (RBV)</intervention_name>
    <description>Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 48 weeks</description>
    <arm_group_label>A1: pegIFNλ+BMS-790052+Placebo for BMS-650032+Ribavirin</arm_group_label>
    <arm_group_label>A2: pegIFNλ+BMS-650032+Placebo for BMS-790052+Ribavirin</arm_group_label>
    <arm_group_label>A3: pegIFNα-2a+PBO for BMS-790052+PBO for BMS-650032+RBV</arm_group_label>
    <other_name>Ribasphere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-650032 (NS3 Protease Inhibitor)</intervention_name>
    <description>Tablets, Oral, 200 mg, Twice daily, 24 weeks</description>
    <arm_group_label>A2: pegIFNλ+BMS-650032+Placebo for BMS-790052+Ribavirin</arm_group_label>
    <arm_group_label>A4: pegIFNλ+BMS-790052+BMS-650032+Ribavirin (24 weeks)</arm_group_label>
    <arm_group_label>A6: pegIFNλ+BMS-790052+BMS-650032+Placebo for RBV (24 weeks)</arm_group_label>
    <other_name>BMS-650032</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pegylated Interferon Alfa-2a (pegIFNα-2a)</intervention_name>
    <description>Solution, Subcutaneous, 180 μg/mL, Once weekly, 48 weeks</description>
    <arm_group_label>A3: pegIFNα-2a+PBO for BMS-790052+PBO for BMS-650032+RBV</arm_group_label>
    <other_name>Pegasys®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pegylated Interferon Lambda (pegIFNλ)</intervention_name>
    <description>Solution, Subcutaneous, 180 μg/mL, Once weekly, 24 weeks</description>
    <arm_group_label>A4: pegIFNλ+BMS-790052+BMS-650032+Ribavirin (24 weeks)</arm_group_label>
    <arm_group_label>A6: pegIFNλ+BMS-790052+BMS-650032+Placebo for RBV (24 weeks)</arm_group_label>
    <other_name>BMS-914143</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin (RBV)</intervention_name>
    <description>Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 24 weeks</description>
    <arm_group_label>A4: pegIFNλ+BMS-790052+BMS-650032+Ribavirin (24 weeks)</arm_group_label>
    <other_name>Ribasphere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pegylated Interferon Lambda (pegIFNλ)</intervention_name>
    <description>Solution, Subcutaneous, 180 μg/mL, Once weekly, 16 weeks</description>
    <arm_group_label>A5: pegIFNλ+BMS-790052+BMS-650032+Ribavirin (16 weeks)</arm_group_label>
    <arm_group_label>A7: pegIFNλ+BMS-790052+BMS-650032+Placebo for RBV (16 weeks)</arm_group_label>
    <other_name>BMS-914143</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin (RBV)</intervention_name>
    <description>Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 16 weeks</description>
    <arm_group_label>A5: pegIFNλ+BMS-790052+BMS-650032+Ribavirin (16 weeks)</arm_group_label>
    <other_name>Ribasphere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-790052 (NS5A Inhibitor)</intervention_name>
    <description>Tablets, Oral, 60 mg, Once daily, 16 weeks</description>
    <arm_group_label>A5: pegIFNλ+BMS-790052+BMS-650032+Ribavirin (16 weeks)</arm_group_label>
    <arm_group_label>A7: pegIFNλ+BMS-790052+BMS-650032+Placebo for RBV (16 weeks)</arm_group_label>
    <other_name>BMS-790052</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-650032 (NS3 Protease Inhibitor)</intervention_name>
    <description>Tablets, Oral, 200 mg, Twice daily, 16 weeks</description>
    <arm_group_label>A5: pegIFNλ+BMS-790052+BMS-650032+Ribavirin (16 weeks)</arm_group_label>
    <arm_group_label>A7: pegIFNλ+BMS-790052+BMS-650032+Placebo for RBV (16 weeks)</arm_group_label>
    <other_name>BMS-650032</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor)</intervention_name>
    <description>Tablets, Oral, 0 mg, Twice daily, 24 weeks</description>
    <arm_group_label>A1: pegIFNλ+BMS-790052+Placebo for BMS-650032+Ribavirin</arm_group_label>
    <arm_group_label>A3: pegIFNα-2a+PBO for BMS-790052+PBO for BMS-650032+RBV</arm_group_label>
    <other_name>Placebo for BMS-650032</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor)</intervention_name>
    <description>Tablets, Oral, 0 mg, Once daily, 24 weeks</description>
    <arm_group_label>A2: pegIFNλ+BMS-650032+Placebo for BMS-790052+Ribavirin</arm_group_label>
    <arm_group_label>A3: pegIFNα-2a+PBO for BMS-790052+PBO for BMS-650032+RBV</arm_group_label>
    <other_name>Placebo for BMS-790052</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Ribavirin (RBV)</intervention_name>
    <description>Tablets, Oral, 0 mg, Twice daily, 24 weeks</description>
    <arm_group_label>A6: pegIFNλ+BMS-790052+BMS-650032+Placebo for RBV (24 weeks)</arm_group_label>
    <other_name>Placebo for Ribasphere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Ribavirin (RBV)</intervention_name>
    <description>Tablets, Oral, 0 mg, Twice daily, 16 weeks</description>
    <arm_group_label>A7: pegIFNλ+BMS-790052+BMS-650032+Placebo for RBV (16 weeks)</arm_group_label>
    <other_name>Placebo for Ribasphere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com.

        Inclusion Criteria:

          -  Chronic Hepatitis C, Genotype 1

          -  HCV RNA &gt;100,000 IU/mL at screening;

          -  Seronegative for Human immunodeficiency virus (HIV) and Hepatitis B surface antigen
             (HBsAg);

          -  Liver biopsy within prior 2 years; subjects with compensated cirrhosis can enroll and
             will be capped at approximately 10%

        Exclusion Criteria:

          -  Any evidence of liver disease other than HCV;

          -  Co-infection with HIV;

          -  Diagnosed or suspected hepatocellular carcinoma;

          -  Medical history or laboratory value abnormalities that would prohibit the use of
             Pegylated Interferon Alpha-2a or Ribavirin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Medical Group Inc.</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Colorado Denver And Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School Of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Lutherville</city>
        <state>Maryland</state>
        <zip>21093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol-Myers Squibb/David E. Bernstein, Md</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Center For Liver Disease</name>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <zip>28677</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke'S Episcopal Hospital - Baylor College Of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Liver Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Research</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Clayton Vic</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6001</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Clichy Cedex</city>
        <zip>92118</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nice Cedex 03</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris Cedex 12</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris Cedex 14</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hiroshima-shi</city>
        <state>Hiroshima</state>
        <zip>7348511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>060-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kawasaki-shi</city>
        <state>Kanagawa</state>
        <zip>2138587</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <zip>5458586</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Iruma-gun</city>
        <state>Saitama</state>
        <zip>3500495</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>105-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Musashino-shi</city>
        <state>Tokyo</state>
        <zip>180-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Grafton</city>
        <state>Auckland</state>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion De Investigacion De Diego</name>
      <address>
        <city>San Juan</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>New Zealand</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2011</study_first_submitted>
  <study_first_submitted_qc>March 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2011</study_first_posted>
  <disposition_first_submitted>September 23, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>September 23, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 9, 2015</disposition_first_posted>
  <last_update_submitted>September 23, 2015</last_update_submitted>
  <last_update_submitted_qc>September 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Antiviral Agents</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Protease Inhibitors</mesh_term>
    <mesh_term>HIV Protease Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

